aTyr Pharma, Inc.
$ 0.49
-4.59%
20 Jul - close price
- Market Cap 47,692,100 USD
- Current Price $ 0.49
- High / Low $ 0.52 / 0.49
- Stock P/E N/A
- Book Value 0.59
- EPS -0.71
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -1.06 %
- 52 Week High 7.29
- 52 Week Low 0.40
About
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$2.86
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-05 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-13 | 2024-11-07 | 2024-08-13 | 2024-05-02 | 2024-03-14 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.11 | -0.14 | -0.26 | -0.22 | -0.17 | -0.1809 | -0.23 | -0.23 | -0.23 | -0.25 | -0.2 | -0.22 |
| Estimated EPS | -0.1425 | -0.18 | -0.18 | -0.18 | -0.19 | -0.226 | -0.22 | -0.24 | -0.25 | -0.24 | -0.22 | -0.27 |
| Surprise | 0.0325 | 0.04 | -0.08 | -0.04 | 0.02 | 0.0451 | -0.01 | 0.01 | 0.02 | -0.01 | 0.02 | 0.05 |
| Surprise Percentage | 22.807% | 22.2222% | -44.4444% | -22.2222% | 10.5263% | 19.9558% | -4.5455% | 4.1667% | 8% | -4.1667% | 9.0909% | 18.5185% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATYR
2026-07-16 18:11:19
H.C. Wainwright has reiterated its Hold rating for ATyr Pharma (ATYR.US). This indicates that the analyst firm recommends investors maintain their current position in the stock. The decision reflects the firm's current assessment of the company's financial outlook and market performance.
2026-07-15 12:46:22
aTyr Pharma (NASDAQ:ATYR) has submitted a Phase 3 study protocol to the FDA for its drug efzofitimod, targeting chronic pulmonary sarcoidosis with restrictive lung disease. This follows positive subgroup analysis from a previous Phase 3 study and the company expects to use forced vital capacity as the primary endpoint. Despite the drug's potential, InvestingPro highlights that aTyr Pharma is currently burning through cash, though it maintains a strong current ratio and more cash than debt.
2026-07-15 11:48:24
aTyr Pharma reported positive subgroup analysis from its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The 44 patients receiving 5.0 mg/kg efzofitimod showed a placebo-adjusted FVC benefit of 123.8 mL at week 48 and improvements in multiple patient-reported outcomes. The company has submitted a protocol to the FDA for a planned Phase 3 study focusing on this specific patient population using FVC as the primary endpoint.
2026-07-15 11:48:24
aTyr Pharma will present a subgroup analysis of its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the WASOG 2026 Congress. The analysis shows that patients with restrictive lung disease treated with efzofitimod demonstrated clinically meaningful benefits in lung function and improvements in patient-reported outcomes. The company has submitted a protocol to the FDA for a planned Phase 3 study focusing on this specific patient population, utilizing FVC as the primary endpoint.
2026-07-15 11:46:22
aTyr Pharma will present a subgroup analysis of its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the WASOG 2026 Congress. The analysis focuses on patients with restrictive lung disease, showing clinically meaningful benefits in lung function and improvements in patient-reported outcomes with efzofitimod. The company recently submitted a protocol to the FDA for a planned Phase 3 study in this specific patient population.
2026-07-15 07:00:00
aTyr Pharma announced it will present subgroup analysis data from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis at the WASOG 2026 Congress. The analysis focuses on patients with restrictive lung disease, showing clinically meaningful benefits in lung function and patient-reported outcomes for those treated with 5.0 mg/kg efzofitimod. The company recently submitted a protocol to the FDA for a planned Phase 3 study for this specific patient population.
